Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

#2115

Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.

Aim(s): The present pooled analysis assessed whether systemic inflammation is associated with poor outcomes among patients (pts) with NET by assessing neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) at baseline.

Materials and methods: Pts with advanced, low-, or intermediate-grade pancreatic (p), gastrointestinal (GI), or lung NETs received either everolimus (EVE) 10 mg/day oral or placebo in RADIANT-3 (p; N=207, N=203) and RADIANT-4 (GI or lung; N=205, N=97) trials. Pts receiving EVE were grouped into NLR high (≥2.58) or low (<2.58) and LMR high (≥3.76) or low (<3.76) groups, based on the median values at baseline. Progression-free survival (PFS; central) was estimated by Kaplan-Meier method and hazard ratio (HR) using adjusted unstratified Cox regression model.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan D, Yao J, Carnaghi C, Buzzoni R, Herbst F,

Keywords: Neuroendocrine tumors, neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, everolimus, RADIANT-3, RADIANT-4, systemic inflammation, prognosis,